Fig. 3From: Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trialKaplan–Meier curves for progression-free survival (a) and overall survival (b)Back to article page